Señales en vivo de PCVX | Maximiza tus Ganancias con Getagraph.com

VENDER 3627 min ago

@ $60.49

Emitido: 26 abr 2024 @ 13:03

Retorno: 0.39%

Señal anterior: abr 26 - 11:21

Señal anterior: Comprar

Retorno: 1.30 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	583 957
Volumen promedio	865 760
Capitalización de mercado	6.60B
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $-1.110 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.67
ATR14	$1.533 (2.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Pickering Grant	Buy	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Stock Option (Right to Buy)
2024-04-18	Guggenhime Andrew	Sell	8 000	Stock Option (right to buy)
2024-04-18	Guggenhime Andrew	Buy	8 000	Common Stock

INSIDER POWER
36.03
Last 100 transactions
Buy: 779 468 \| Sell: 362 821

Volumen Correlación

Largo: -0.43 (neutral)

Corto: 0.88 (strong)

Signal:(68) Same movement expected

Vaxcyte Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaxcyte Inc Correlación - Moneda/Commodity

0.31
( neutral )

-0.14
( neutral )

0.00
( neutral )

0.08
( neutral )

-0.40
( neutral )

-0.26
( neutral )

Vaxcyte Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-9.20M (0.00 %)
EPS:	$-3.69

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.